FindTrial
Sign In

pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine

BIOLOGICAL2 trials

Sponsors

University of Washington

Conditions

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2/Neu NegativeNo Evidence of DiseaseOne or More Positive Axillary NodesStage IB Breast CancerStage II Breast Cancer

Phase 1

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
CompletedNCT02780401
University of WashingtonHER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes +8
Start: 2016-09-02End: 2022-10-08Updated: 2024-09-19

Phase 2

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
RecruitingNCT04329065
University of WashingtonAnatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Start: 2022-04-20End: 2027-12-31Target: 25Updated: 2026-05-19

Related Papers

A phase II study of concurrent WOKVAC vaccination with neoadjuvant chemotherapy and HER2-targeted monoclonal antibody therapy.
Journal of Clinical Oncology2023-06-014 citations
Abstract P2-02-02: Phase I trial of the safety and immunogenicity of a tri-antigen vaccine targeting HER2, IGFBP-2, and IGF-IR in patients with non-metastatic breast cancer
Cancer Research2023-03-013 citations
Role of Immune Response in Breast Cancer Vaccines
Oncology Times2017-02-28